Boston-based medtech company Clairity today announced that it has appointed Joe Kiani as chairman of the board of directors.
The company developed an AI-powered risk assessment platform for breast cancer, which received FDA de Novo authorization last year. The platform analyzes standard screening mammograms to estimate a woman’s five-year risk of developing breast cancer for earlier intervention.
“Clairity is at a defining moment,” Kiani said in a statement. “With FDA De Novo authorization and growing demand from health systems, the company is uniquely positioned to lead the next era of breast cancer screening and prevention through its risk prediction platform.”
Kiani founded Irvine-based medical device maker Masimo Corp., which went public in 2007 and has grown its market cap to more than $7 billion, as well as a newer diabetes venture called Willow Laboratories.
Clairity also appointed its founder Connie Lehman to the role of chief executive.
The company raised a $43 million Series B round in 2025 to support commercialization and expanded clinical adoption of its technology.
